U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C13H18N2O.C4H6O4
Molecular Weight 336.3829
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Mebufotenin succinate

SMILES

OC(=O)CCC(O)=O.COC1=CC2=C(NC=C2CCN(C)C)C=C1

InChI

InChIKey=QGPJMYNZUUBWLQ-UHFFFAOYSA-N
InChI=1S/C13H18N2O.C4H6O4/c1-15(2)7-6-10-9-14-13-5-4-11(16-3)8-12(10)13;5-3(6)1-2-4(7)8/h4-5,8-9,14H,6-7H2,1-3H3;1-2H2,(H,5,6)(H,7,8)

HIDE SMILES / InChI

Molecular Formula C4H6O4
Molecular Weight 118.088
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C13H18N2O
Molecular Weight 218.2948
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

N,N-Dimethyl-5-Methoxytryptamine (aka 5-MeO-DMT) is a psychedelic of the tryptamine class. It is found in a wide variety of plant species, and a single psychoactive toad species, the Colorado River toad. Like its close relatives DMT and bufotenin (5-HO-DMT), it has been used as an entheogen in South America. It can also be found in the dart poison traditionally used by the Yanoama Indians of Upper Orinoco. It acts as a non-selective serotonin (5-HT) agonist. -MeO-DMT is O-demethylated by polymorphic cytochrome P450 2D6 (CYP2D6) to an active metabolite, bufotenine. 5-MeO-DMT is classified as a controlled substance in China, Australia, Sweden, Turkey, and the USA.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
The hallucinogenic world of tryptamines: an updated review.
2015-08
Schedules of controlled substances: placement of 5-methoxy-N,N-dimethyltryptamine into Schedule I of the Controlled Substances Act. Final rule.
2010-12-20
Hearing loss alters serotonergic modulation of intrinsic excitability in auditory cortex.
2010-11
Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions.
2010-10
Intrahippocampal LSD accelerates learning and desensitizes the 5-HT(2A) receptor in the rabbit, Romano et al.
2010-10
Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.
2010-07-01
Early-life treatment of antiserotonin antibodies alters sensitivity to serotonin receptors, nociceptive stimulus and serotonin metabolism in adult rats.
2010-06
LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT(2A) receptor.
2010-02
Human and mouse trace amine-associated receptor 1 have distinct pharmacology towards endogenous monoamines and imidazoline receptor ligands.
2009-10-23
Endogenous hallucinogens as ligands of the trace amine receptors: a possible role in sensory perception.
2009-01
Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors.
2008-11
Indolealkylamines: biotransformations and potential drug-drug interactions.
2008-06
Solubilization of 5-methoxy tryptamine molecular probes in CTAB and SDS micelles: a cmc and binding constant study.
2008-03
Comparison of the separation of nine tryptamine standards based on gas chromatography, high performance liquid chromatography and capillary electrophoresis methods.
2008-02-15
Delta 9-tetrahydrocannabinol-induced catalepsy-like immobilization is mediated by decreased 5-HT neurotransmission in the nucleus accumbens due to the action of glutamate-containing neurons.
2008-01-24
A general approach to the screening and confirmation of tryptamines and phenethylamines by mass spectral fragmentation.
2008-01-15
Neurobiology of spirituality.
2008-01
In vitro screening of psychoactive drugs by [(35)S]GTPgammaS binding in rat brain membranes.
2007-12
The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain.
2007-03-22
Analysis of hallucinogenic constituents in Amanita mushrooms circulated in Japan.
2006-12-20
Efficient and sensitive method for quantitative analysis of alkaloids in hardinggrass (Phalaris aquatica L.).
2006-12-13
The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats.
2006-12
Human trabecular meshwork cells express functional serotonin-2A (5HT2A) receptors: role in IOP reduction.
2006-09
A demand for clarity regarding a case report on the ingestion of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) in an Ayahuasca preparation.
2006-07-29
A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation.
2005-12-17
Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies.
2005-11-30
Suppressive effects of isorhynchophylline on 5-HT2A receptor function in the brain: behavioural and electrophysiological studies.
2005-07-11
The rapid analysis of heroin drug seizures using micellar electrokinetic chromatography with short-end injection.
2005-01
Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile.
2004-09
The Meixner test in the detection of alpha-amanitin and false-positive reactions caused by psilocin and 5-substituted tryptamines.
2004-08
Binding of tryptamine analogs at h5-HT1E receptors: a structure-affinity investigation.
2004-05-15
Pharmacological characterization of a serotonin receptor (5-HT7) stimulating cAMP production in human corneal epithelial cells.
2003-11
Identification of cytokinins produced by the plant parasitic nematodes Heterodera schachtii and Meloidogyne incognita.
2003-07-01
Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys.
2003-07
Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase.
2003-06
The role of 5-HT(1A) receptors in control of lower urinary tract function in cats.
2002-08-16
Involvement of 5-hydroxytryptamine neuronal system in Delta(9)-tetrahydrocannabinol-induced impairment of spatial memory.
2002-06-12
5-HT2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens.
2002-05
Pharmepéna-Psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine.
2002-02-05
[(3)H]-serotonin release from bovine iris-ciliary body: pharmacology of prejunctional serotonin (5-HT(7)) autoreceptors.
2001-07
Distribution of the hallucinogens N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine in rat brain following intraperitoneal injection: application of a new solid-phase extraction LC-APcI-MS-MS-isotope dilution method.
2001-02-10
Determination of potentially hallucinogenic N-dimethylated indoleamines in human urine by HPLC/ESI-MS-MS.
2001
Effects of serotoninergic drugs on tremor induced by physostigmine in rats.
2000-05
High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action.
1999-05
Identification of residues in transmembrane regions III and VI that contribute to the ligand binding site of the serotonin 5-HT6 receptor.
1998-11
Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype.
1993-08-25
Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase.
1993-01-15
[Methylated and unmethylated indolamine in the cisternal fluid in acute endogenous psychoses].
1983
Repeated chlorpromazine administration increases a behavioural response of rats to 5-hydroxytryptamine receptor stimulation.
1977-02
Patents

Sample Use Guides

10 mg of 5-MeO-DMT administrated intranasally or sublingually causes a significant visionary response.
Route of Administration: Other
Membranes were prepared from the cerebral cortex and striatum of Male SD rats and maintained in HEPES buffer pH 7.6, 20 mM HEPES, 7 mM MgCl2, 100 mM NaCl, 1 mM EDTA, 0.2 mM dithiothreitol (DTT). Cells were plated in 96 wells containing an assay buffer of 25 mM HEPES, pH 7.6, 7 mM MgCl2, 100 mM NaCl, 1 mM EDTA, 0.2 mM DTT and 10 mM DPCPX. Each well also received various concentrations screening compounds, DA, 5-HT, NE, and the mixture of brain membranes (2 mg protein/well for the striatum and 4 mg protein/well for the cortex) and 150 micro-M GDP. This mixture was pre-incubated at 30 °C for 20 minutes with shaking. Incubation was started by adding 0.1 nM [35S]GTPgS to a total volume of 100 mL and continued at 30 °C for 90 minutes with shaking. The reaction was stopped by rapid filtration and retained membrane-bound radioactivity on the filter was measured by liquid scintillation counting. 5-MeODMT was found to have an EC50 of 3.8 x 10^07 M.
Substance Class Chemical
Created
by admin
on Wed Apr 02 14:33:36 GMT 2025
Edited
by admin
on Wed Apr 02 14:33:36 GMT 2025
Record UNII
BN4EF8WH5L
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Mebufotenin succinate
Common Name English
5-methoxydimethyltryptamine succinate
Preferred Name English
Butanedioic acid, compd. with 5-methoxy-N,N-dimethyl-1H-indole-3-ethanamine (1:1)
Systematic Name English
3-[2-(Dimethylamino)ethyl]-5-methoxyindole succinate
Systematic Name English
Code System Code Type Description
FDA UNII
BN4EF8WH5L
Created by admin on Wed Apr 02 14:33:36 GMT 2025 , Edited by admin on Wed Apr 02 14:33:36 GMT 2025
PRIMARY
CAS
2568048-63-3
Created by admin on Wed Apr 02 14:33:36 GMT 2025 , Edited by admin on Wed Apr 02 14:33:36 GMT 2025
PRIMARY
PUBCHEM
164886348
Created by admin on Wed Apr 02 14:33:36 GMT 2025 , Edited by admin on Wed Apr 02 14:33:36 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE